AXLA

In a report released on August 12, Thomas Smith from SVB Securities maintained a Buy rating on Axcella Health (AXLA - Research Report), with a price target of $6.00. The company's shares closed yesterday at $2.65.According to TipRanks, Smith is an analyst with an average return of -10.1% and a 38.14% success rate. Smith covers the Healthcare sector, focusing on stocks such as Prometheus Biosciences, MannKind, and Madrigal Pharmaceuticals.Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $8.00, a 201.89% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.
https://www.tipranks.com/news/blurbs/svb-securities-remains-a-buy-on-axcella-health-axla?utm_source=advfn.com&utm_medium=referral